These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30020258)

  • 21. Multiple action agents and the eye: do they really stabilize mast cells?
    Lambiase A; Micera A; Bonini S
    Curr Opin Allergy Clin Immunol; 2009 Oct; 9(5):454-65. PubMed ID: 19652595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of olopatadine for the treatment of ocular allergy.
    Abelson MB
    Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of olopatadine and selected antihistamines with model and natural membranes.
    Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM
    Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].
    Hida WT; Nogueira DC; Schaefer A; Dantas PE; Dantas MC
    Arq Bras Oftalmol; 2006; 69(6):851-6. PubMed ID: 17273679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
    Abelson MB; Gomes PJ; Pasquine T; Edwards MR; Gross RD; Robertson SM
    Allergy Asthma Proc; 2007; 28(4):427-33. PubMed ID: 17883910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis.
    Dudeja L; Janakiraman A; Dudeja I; Sane K; Babu M
    Indian J Ophthalmol; 2019 Sep; 67(9):1400-1404. PubMed ID: 31436181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
    Beauregard C; Stephens D; Roberts L; Gamache D; Yanni J
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
    McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G
    Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms.
    Ahluwalia P; Anderson DF; Wilson SJ; McGill JI; Church MK
    J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV; Udell IJ
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
    Aguilar AJ
    Acta Ophthalmol Scand Suppl; 2000; (230):52-5. PubMed ID: 11057352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents.
    Shulman DG; Amdahl L; Washington C; Graves A
    Clin Ther; 2003 Apr; 25(4):1096-106. PubMed ID: 12809959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alcaftadine for the prevention of itching associated with allergic conjunctivitis.
    Mahvan TD; Buckley WA; Hornecker JR
    Ann Pharmacother; 2012; 46(7-8):1025-32. PubMed ID: 22811343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of olopatadine versus epinastine for treating allergic conjunctivitis caused by Japanese cedar pollen: a double-blind randomized controlled trial.
    Fukushima A; Ebihara N
    Adv Ther; 2014 Oct; 31(10):1045-58. PubMed ID: 25269854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
    Galatowicz G; Ajayi Y; Stern ME; Calder VL
    Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
    Pipkorn P; Costantini C; Reynolds C; Wall M; Drake M; Sanico A; Proud D; Togias A
    Ann Allergy Asthma Immunol; 2008 Jul; 101(1):82-9. PubMed ID: 18681089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In brief: OTC alcaftadine (Lastacaft Once Daily Relief) for allergic conjunctivitis.
    Med Lett Drugs Ther; 2022 May; 64(1650):78. PubMed ID: 35536123
    [No Abstract]   [Full Text] [Related]  

  • 39. Treating severe eye allergy.
    Verin P
    Clin Exp Allergy; 1998 Dec; 28 Suppl 6():44-8. PubMed ID: 9988435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
    Mah FS; O'Brien T; Kim T; Torkildsen G
    Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.